Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
5-year Survival
14%
Adverse Events
14%
Antitumor
14%
Antitumor Effect
14%
Borderline Resectable Pancreatic Cancer
100%
Chemotherapy
14%
Chemotherapy Treatment
28%
Clinical Trials
14%
Combination Therapy
14%
Complete Response
14%
Direct Injection
28%
Dose Escalation
14%
Dose-limiting Toxicity
14%
Downstaging
14%
Duodenum
14%
Efficacy Assessment
14%
Endoscopic Ultrasound-guided
100%
Erlotinib
28%
Every 2 weeks
14%
Gemcitabine
28%
Hepatic Dysfunction
14%
Herpes Simplex Virus Type 1 (HSV-1)
14%
HF10
100%
Intratumoral Injection
100%
Locally Advanced Pancreatic Cancer
14%
Malignancy
14%
Median Overall Survival
14%
Median Progression-free Survival
14%
Mid-term Outcomes
14%
Myelosuppression
14%
Oncolytic Virus
100%
Overall Survival
14%
Pancreatic Cancer
14%
Partial Response
14%
Patient Will
14%
Perforation
14%
Phase I Dose-escalation Trials
14%
Phase I Trial
100%
Progressive Disease
14%
Response Rate
14%
Safe Treatment
14%
Safety Assessment
14%
Serious Adverse Events
14%
Stable Disease
14%
Target Lesion
14%
Tumor Response
14%
Medicine and Dentistry
Adverse Event
28%
Arm
14%
Bone Marrow Suppression
14%
Cancer
14%
Canerpaturev
100%
Chemotherapy
42%
Clinical Trial
100%
Combination Therapy
14%
Diseases
14%
Duodenum
14%
Efficacy Assessment
14%
Endoscopic Ultrasound
100%
Erlotinib
28%
Gemcitabine
28%
Human Alphaherpesvirus 1
14%
Injection
28%
Intratumoral Drug Administration
100%
Liver Dysfunction
14%
Neoplasm
28%
Oncolytic Virus
100%
Overall Survival
28%
Pancreas Cancer
100%
Phase I Trials
14%
Progression Free Survival
14%
Progressive Disease
14%
Prospective Study
14%
Safety Assessment
14%
Survival Rate
14%
Target Lesion
14%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Duodenum
50%
Efficacy Assessment
50%
Erlotinib
100%
Gemcitabine
100%
Human Alphaherpesvirus 1
50%
Overall Survival
100%
Phase I Trials
50%
Progression Free Survival
50%
Prospective Study
50%
Survival Rate
50%
Virus
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
28%
Bone Marrow Suppression
14%
Canerpaturev
100%
Chemotherapy Regimens
42%
Clinical Trial
100%
Combination Therapy
14%
Diseases
28%
Efficacy Assessment
14%
Erlotinib
28%
Gemcitabine
28%
Human Alphaherpesvirus 1
14%
Liver Dysfunction
14%
Neoplasm
28%
Oncolytic Virus
100%
Overall Survival
28%
Pancreas Cancer
100%
Phase I Trials
14%
Progression Free Survival
14%
Prospective Study
14%
Safety Assessment
14%
Survival Rate
14%